The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The FDA grants MRG-106 Orphan Drug Designation for Mycosis Fungoides type Cutaneous T-Cell Lymphoma

Apr 11, 2017

On 31 stMarch 2017, the U.S. Food and Drug Administration ( FDA) granted Orphan Drug Designation status to MRG-106 for the treatment of Mycosis Fungoides type Cutaneous T-Cell Lymphoma (MF-CTCL).

MicroRNA-155 has been reported at aberrantly high levels in a range of hematological malignancies and has various roles in differentiation and proliferation of blood cells and lymphocytes. miRagen Therapeutics’MRG-106 is a microRNA-155 inhibitor.

Currently, the safety, tolerability, and pharmacokinetics of intravenous MRG-106 is being evaluated in a phase I clinical trial ( NCT02580552) of patients with MF-CTCL. The estimated primary completion date is July 2017.

  1. Street Insider. miRagen Therapeutics (MGEN) Receives Orphan-Drug Designation for MRG-106 to Treat Mycosis Fungoides. 2017 Mar 31. [Accessed 2017 Apr 11].